Oncotarget

Vol 9, No 87

November 6, 2018

View Archive »

Order a Reprint

About The Cover

The cover for issue 87 of Oncotarget features Figure 1, "The survival rate of genetically engineered mice with pancreatic ductal adenocarcinoma treated with a weekly injection of nano-albumin bound paclitaxel (NAB-paclitaxel) alone (orange line, n = 4), NAB-paclitaxel 3 hours after CYT-6091 treatment (green line, n = 4), and vehicle control (blue line, n = 3)," by Libutti, et al.

Table of Contents

News

MiRNAs prognostic for basal and BRCA1 breast cancer

MiRNAs prognostic for basal and BRCA1 breast cancer

https://doi.org/10.18632/oncotarget.26297

Bhupinder Pal,  and Robin L. Anderson
35717-35718
PDF  |  Order a Reprint

Editorial

A triple drug combination as a novel anti-glioma therapy?

A triple drug combination as a novel anti-glioma therapy?

https://doi.org/10.18632/oncotarget.26279

Yiru Zhang, Georg Karpel-Massler,  and Markus D. Siegelin
35719-35720
PDF  |  Order a Reprint

Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD

Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD

https://doi.org/10.18632/oncotarget.26291

Kidist Ashami, John F. DiPersio,  and Jaebok Choi
35721-35722
PDF  |  Order a Reprint

Research Perspectives

Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure

Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure

https://doi.org/10.18632/oncotarget.26267

Steven K. Libutti, Lawrence Tamarkin,  and Naris Nilubol
35723-35725
Abstract  |  PDF  |  HTML  |  Order a Reprint

Research Papers

Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma

Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma

https://doi.org/10.18632/oncotarget.26284

Steven Georges, Lidia Rodriguez Calleja, Camille Jacques, Melanie Lavaud, Brice Moukengue, Fernando Lecanda, Thibaut Quillard, Marta Tellez Gabriel, Pierre-François Cartron, Marc Baud’huin, François Lamoureux, Dominique Heymann,  and Benjamin Ory
35726-35741
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Histologic subtyping in pathologic stage I-IIA lung adenocarcinoma provides risk-based stratification for surveillance

Histologic subtyping in pathologic stage I-IIA lung adenocarcinoma provides risk-based stratification for surveillance

https://doi.org/10.18632/oncotarget.26285

Yusuke Takahashi, Takashi Eguchi, Koji Kameda, Shaohua Lu, Raj G. Vaghjiani, Kay See Tan, William D. Travis, David R. Jones,  and Prasad S. Adusumilli
35742-35751
Abstract  |  PDF  |  HTML  |  Order a Reprint

Immunomodulatory effect of statins on Regulatory T Lymphocytes in human colorectal cancer is determined by the stage of disease

Immunomodulatory effect of statins on Regulatory T Lymphocytes in human colorectal cancer is determined by the stage of disease

https://doi.org/10.18632/oncotarget.26293

Belal A. Al-Husein, Bara’ Dawah, Saleem Bani-Hani, Samir M. Al Bashir, Khaled M. Al-Sawalmeh,  and Nehad M. Ayoub
35752-35761
Abstract  |  PDF  |  HTML  |  Order a Reprint

Cytotoxicity of nimbolide towards multidrug-resistant tumor cells and hypersensitivity via cellular metabolic modulation

Cytotoxicity of nimbolide towards multidrug-resistant tumor cells and hypersensitivity via cellular metabolic modulation

https://doi.org/10.18632/oncotarget.26299

Nuha Mahmoud, Mohamed E.M. Saeed, Yoshikazu Sugimoto, Sabine M. Klauck, Henry J. Greten,  and Thomas Efferth
35762-35779
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Clinical Research Papers

Bloodstream infection due to Escherichia coli in liver cirrhosis patients: clinical features and outcomes

Bloodstream infection due to Escherichia coli in liver cirrhosis patients: clinical features and outcomes

https://doi.org/10.18632/oncotarget.23200

Bo Tu, Jingfeng Bi, Dan Wu, Peng Zhao, Lei Shi, Yangxin Xie, Xin Zhang, Zhe Xu, Suxia Liu, Xinhua Wang, Xiaoxi Li, Fusheng Wang,  and Enqiang Qin
35780-35789
Abstract  |  PDF  |  HTML  |  Order a Reprint

Reviews

Attaining threshold antibody cytotoxicity for selective tumor cell destruction: an opinion article

Attaining threshold antibody cytotoxicity for selective tumor cell destruction: an opinion article

https://doi.org/10.18632/oncotarget.26271

Victor I. Seledtsov,  and Galina V. Seledtsova
35790-35794
Abstract  |  PDF  |  HTML  |  Order a Reprint

Corrections

Correction: Proteomic screening identifies the zonula occludens protein ZO-1 as a new partner for ADAM12 in invadopodia-like structures

Correction: Proteomic screening identifies the zonula occludens protein ZO-1 as a new partner for ADAM12 in invadopodia-like structures

https://doi.org/10.18632/oncotarget.26339

Bassil Dekky, Michael Ruff, Dominique Bonnier, Vincent Legagneux,  and Nathalie Théret
35795-35795
Correction  |  PDF

Correction: The path to « the Golden Age » for the treatment of metastatic renal cell carcinoma

Correction: The path to « the Golden Age » for the treatment of metastatic renal cell carcinoma

https://doi.org/10.18632/oncotarget.26340

Gilles Pagès
35796-35796
Correction  |  PDF


Copyright © 2018 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC